The +0.7% Hidden Inside Kusuri No Aoki's +10.7% Headline

A Japanese drugstore just told investors it grew sales 10.7% in a single month, and the stock has run up more than a fifth in three months. The market, understandably, is paying attention. The mistake would be reading the number the way the headline invites you to.

Here is the fact those headlines leave out: the same drugstore's comparable-store sales — the figure that isolates how much existing, established stores grew — rose just 0.7% in that same month. In July it was 0.3%. The eye-catching number counts every store the company has opened, bought, or expanded. The quiet number measures whether the stores it already had are actually selling more.

That gap between a 10.7% headline and a 0.7% core is the whole story at Kusuri No Aoki Holdings (TSE:3549), and it deserves a closer look than the monthly update attracted.

How a drugstore can grow 10% and barely grow at all

"All-store sales" in Japanese retail means sales across the entire network, every location open today. "Existing-store sales" (sometimes called same-store or comparable-store) tracks only stores that were open in both this year and last. The two diverge when a company is aggressively opening and acquiring. That is exactly what Kusuri No Aoki is doing — and the divergence tells you which growth is real demand and which is just a bigger footprint.

In August 2026, all-store sales rose 10.7% year over year while existing-store sales rose 0.7%. In July, all-store rose 9.6% while existing-store rose 0.3%. Roughly ten percentage points of that headline growth each month comes from new and expanded stores, not from the company selling more at the stores it already runs. A reader of only the top line would walk away thinking the business is booming. A reader of the comparable figure would ask a harder question: what if the customer isn't shopping more, and the company is only succeeding at building more stores?

The audited year settles the question. For the fiscal year ended May 2026, Kusuri No Aoki grew revenue 13% to ¥567 billion. Operating profit rose just 1.9% to ¥27 billion, and operating margin slipped to 4.8% from 5.3%. Net profit actually fell 3.7%. Record-ish top-line growth, shrinking bottom-line profit. That is not the signature of a business printing money from strong demand; it is the signature of a business paying heavily to add sales.

The expansion is feeding on the balance sheet

Nobody should be shocked that this doesn't yet show up in profit, because the strategy is capital-hungry by design. Kusuri No Aoki started as a regional dispensing-pharmacy chain and has spent the last several years buying its way into fresh food — a dozen-plus companies acquired in four years, including supermarkets. The Shashi history notes the company itself acknowledged it lacked the sourcing networks and store-operating know-how for fresh food and had to buy them. Supermarket food is low-margin and operationally brutal. You can grow revenue fast by swallowing it; converting it into profit is another matter.

The bill for that build-out is visible on the balance sheet. Over fiscal 2026, interest-bearing debt rose nearly 29% to ¥120 billion, the debt-to-equity ratio jumped about 21 percentage points to 85%, and the equity ratio fell 7 points to 34.3%. None of this is fatal on its own for a retailer with ¥141 billion of equity. But it is the wrong shape for a stock the market is treating as a momentum story: the company is levering up to buy growth that, so far, is not improving per-share earnings.

Management's own forecast for the year ending May 2027 — operating profit up about 18% to ¥32 billion — is effectively a bet that the margin damage reverses. At the current price near ¥4,000, the stock carries a price-to-earnings ratio in the low-20s. That is a growth-stock multiple for a company whose net profit shrank 3.7% after a 13% revenue jump. The market has not merely priced success; it has priced the margin recovery management must now deliver.

The family is fortifying, not distributing

The second thing the monthly headline obscures is that this company, while it was busy buying supermarkets, also spent the year rearranging its own ownership in ways that matter far more to minority shareholders than one month's sales.

Kusuri No Aoki is a nearly 160-year-old family business. Its roots run to 1869, and it is run by two brothers, the sixth generation of the founding family, after their father — the founder — died in May 2024. This is normally the kind of detail a stock watcher files away. It became the center of the story in early 2026.

In January 2026 the company ended its long-standing business and capital alliance with Aeon, a partner since 2003. In February, it pushed through a poison-pill takeover defense, passed with about 55.5% shareholder approval, aimed at diluting any buyer crossing a 20% stake threshold. It moved off the Tokyo Stock Exchange's Prime market to the lower Standard market, and listed separately on the Nagoya Stock Exchange. Along the way, an activist fund — Oasis Management, holding roughly 11.8% — mounted a public campaign against the takeover defense, alleging self-dealing and specifically objecting to stock options the founding brothers exercised at a more-than-99% discount to fair value, which Oasis calculates diluted existing shareholders by about 11%.

Whether you accept Oasis's framing or not, step back and look at the sequence. In roughly a year, the founding family concentrated its control, terminated the big-partner alliance that had given the small chain buying power, adopted a poison pill, and moved itself to a less-scrutinized market listing — while the network heavily levered up to buy growth. One of those things is expansion. The other is a company reorganizing so that expansion happens on the family's terms, with less outside voice.

The alliance breakup is worth pausing on for the competitive stakes. Aeon's own drugstore arm, Welcia, has merged with Tsuruha to form Japan's largest drugstore group — more than ¥2 trillion in revenue and over 5,600 stores. Kusuri No Aoki, with roughly ¥567 billion in revenue and just past a thousand stores, is now negotiating that consolidating industry alone, and buying supermarkets to bulk up for it. And note the industry's economics: even the giants' operating margins have been stuck in the low single digits. A small competitor buying low-margin food to outgrow a ¥2 trillion rival is a strategy with an expensive, uncertain ending.

What the flat number actually measures

The contrarian reading here is not that Kusuri No Aoki is a bad company. It is a real retailer with a real foot in the durable pharmacy business, and it is entirely possible the supermarket expansion eventually matures into profit. The point is what the current price is being asked to believe.

The monthly headline that drew the attention — sales up 10.7% — is the least informative number the company publishes, because it counts the roofs it added rather than the stores that are succeeding. The number that answers the actual investment question — are customers spending more at stores the company already owns? — is 0.7%. And the audited results already told you what unprofitable growth looks like: 13% more revenue bought a 22x-earnings company a falling net profit and a weaker balance sheet.

Here is the beauty of the existing-store metric as a referee: it lets a skeptic watch for genuine improvement without having to predict store counts. If comparable-store sales start climbing — sustainably moving from 0.7% toward the low-to-mid single digits — then the margin recovery management has forecast has a real foundation, and this becomes a genuine compounding story that has simply been early. The build-out will have produced profit, not just square footage.

If comparable-store sales stay near zero while the company keeps buying shelves, though, then the rally has been built on the wrong denominator all along. The stock would be a perpetual raiser of capital buying growth that never reaches the last line — and the poison-pill defense means the normal adult supervision, the takeover that would force efficiency and distribute value, is now expressly off the table.

No single month answers which path we are on. But the +0.7% inside the +10.7% is the number worth straining to hear past all the noise. Getting the denominator right — demand per store, profit per yen of expansion capital, not shelf count — is what separates understanding this stock from merely applauding its monthly press release. The crowd has already paid for the headline. The investor needs to know what the flat line underneath it is worth.